Routine

HIV/AIDS

Infection · Infectious Disease
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Chronic infection with human immunodeficiency virus causing progressive CD4 T-cell depletion and, untreated, AIDS; lifelong antiretroviral therapy restores immunity and renders the person non-infectious (U=U).

Red flags

  • Manage through specialist HIV/ART services
  • Admit for serious opportunistic infection, severe IRIS, advanced disease or significant drug toxicity
  • Urgent referral for pregnancy, treatment failure, resistance and complex co-infection (TB, viral hepatitis)

Assessment

Investigations

  • HIV antigen/antibody (4th-generation) screen with confirmatory testing; baseline CD4 count and HIV RNA viral load
  • Screen for TB, hepatitis B and C, syphilis, cryptococcal antigen (if CD4 <100) and other STIs
  • HLA-B*5701 before abacavir where used; monitor renal and metabolic parameters on treatment

Management

  • Start antiretroviral therapy in everyone, regardless of CD4
  • Preferred first-line: tenofovir + lamivudine (or emtricitabine) + dolutegravir (TLD, single pill)
  • Give opportunistic-infection prophylaxis (co-trimoxazole if CD4 <200; treat/latent-treat TB) and manage any active OI, timing ART to avoid severe IRIS (defer in TB and cryptococcal meningitis)
  • Offer prevention: PrEP, PEP and partner testing
  • India provides free ART via NACO/ART centres

Disposition

Manage through specialist HIV/ART services.

Complications & pitfalls

  • Opportunistic infections and malignancies, immune reconstitution inflammatory syndrome, HIV-associated nephropathy and neurocognitive disorder, accelerated cardiovascular disease, and treatment failure with resistance
  • Untreated disease is fatal

Exam pearls

  • Test early and treat immediately: anyone presenting with TB, unexplained weight loss or an unusual infection warrants an HIV test, and a suppressed viral load means no onward transmission.
  • Monitoring & follow-up: Viral load at 6 months then 6-12 monthly, aiming for undetectable; CD4 recovery, adherence support and resistance testing on virological failure. Screen for non-communicable disease, bone, renal and lipid effects, cervical/anal cytology, and vaccinate. Reinforce that undetectable = untransmittable (U=U).

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.